ReviewCNS drugs2007
Oral disease-modifying treatments for multiple sclerosis: the story so far.
Review in CNS drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Synthesis of 1,2-dihydro-2-oxo-4-quinolinyl phosphates from 2-acyl-benzoic acids.Tetrahedron letters · 2015Article
- Effects of Panax ginseng in Neurodegenerative Diseases.Journal of ginseng research · 2012Article
- Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.CNS drugs · 2011Review
- Cladribine tablets: in relapsing-remitting multiple sclerosis.CNS drugs · 2011Review
- Animal models of multiple sclerosis--potentials and limitations.Progress in neurobiology · 2010Review
- Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.Drug design, development and therapy · 2010Review
- Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.Journal of neurology · 2009Article
- Review of teriflunomide and its potential in the treatment of multiple sclerosis.Neuropsychiatric disease and treatment · 2009Article
- Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.Journal of neurology · 2008Review
- Immunomodulatory treatment strategies in multiple sclerosis.Journal of neurology · 2008Review
- Escalating immunotherapy of multiple sclerosis.Therapeutic advances in neurological disorders · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the CNS. It is the most common cause of neurological disability in young adults and exhibits considerable clinical, radiological and pathological heterogeneity. Increased understanding of the immunopathological processes underlying this disease, advances in biotechnology and the development of powerful magnetic resonance imaging (MRI) technologies, together with improvements in clinical trial design, have led to a variety of valuable therapeutic approaches to MS. Therapy for MS has changed dramatically over the past decade, yielding significant progress in the treatment of relapsing remitting and secondary progressive forms; however, most of the clinically relevant therapeutic approaches are not yet available as oral formulations. A substantial number of preliminary and pivotal reports have provided promising results for oral therapies, and various phase III clinical trials are currently being initiated or are already underway evaluating the efficacy of a variety of orally administered agents, including cladribine, teriflunomide, laquinimod, fingolimod and fumaric acid. It is hoped that these trials will advance the development of oral therapies for MS.
Indexed as
Identifiers
17521228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.